AbilityPharma

Ability Pharmaceuticals is dedicated to advancing cancer treatment through innovative therapeutics targeting cell membranes. Located in Barcelona, Spain, the company specializes in the discovery and development of novel drugs for cancer and other diseases with unmet medical needs. Their focus lies in creating innovative therapies for lung and pancreatic cancer by leveraging Lipid Analogue Therapeutics. This new class of drugs has the potential to reorganize lipid structures within the cell membrane, leading to the formation of non-lamellar phase structures. Their pipeline includes ABTL0812, currently in preclinical development, and ABTL1014, a drug candidate undergoing preclinical characterization. Founded in 2009, Ability Pharmaceuticals operates in the Biotechnology, Health Care, and Pharmaceutical industries. Its most recent investment was a €7.00M Venture Round on 11 March 2024, with participation from Inveready, CTI Life Sciences Fund, European Innovation Council, Fitalent, CDTI Innovación's INNVIERTE program, GESAMO family office, and IVAMOSA family office. Overall, Ability Pharmaceuticals stands as a promising player in the biotech industry with a focus on pioneering cancer therapeutics.